Home › Trials › NCT02325674

Registry for patients treated with metreleptin for lipodystrophy

MEASuRE: Metreleptin Effectiveness And Safety Registry

Amryt Pharma · NCT02325674

This study is collecting information from patients with lipodystrophy who are being treated with metreleptin to see how well it works and what side effects it might cause in real life.

Quick facts

Study typeObservational
Enrollment100 (estimated)
SexAll
SponsorAmryt Pharma (industry)
Locations28 sites (Birmingham, Alabama and 27 other locations)
Trial IDNCT02325674 on ClinicalTrials.gov

What this trial studies

This is a prospective, observational registry that collects data on patients receiving metreleptin treatment for generalized and partial lipodystrophy. The study aims to gather real-world evidence on the safety and effectiveness of metreleptin, focusing on various adverse events and treatment outcomes. Patients enrolled in the registry will be monitored for complications such as pancreatitis, hepatic events, and autoimmune disorders, contributing to a better understanding of metreleptin's impact in routine clinical practice.

Who should consider this trial

Good fit: Ideal candidates for this registry are patients currently receiving metreleptin treatment or those transitioning from clinical trials to commercial treatment.

Not a fit: Patients currently participating in investigational clinical trials with other agents will not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could provide valuable insights into the long-term safety and effectiveness of metreleptin, improving treatment strategies for patients with lipodystrophy.

How similar studies have performed: Other observational studies have successfully provided insights into treatment outcomes for similar conditions, suggesting that this approach could yield meaningful data.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients treated with metreleptin through commercial supply at the time or before enrolment into registry
* Patients who provide a written consent
* Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply

Exclusion Criteria:

• Patients currently treated with an investigational agent as part of a clinical trial

Where this trial is running

Birmingham, Alabama and 27 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Generalised Lipodystrophy, Partial Lipodystrophy, Lipodystrophy, Metreleptin Registry

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.